Results 111 to 120 of about 648 (164)

Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study. [PDF]

Neurol Clin Pract
Balshi A, Leuenberger G, Dempsey J, Manning N, Baber U, Sloane JA.   +5 more
europepmc   +1 more source

Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry. [PDF]

Neurol Ther
Braune S, Dirks P, Colloud S, Wang Q, Davies E, Heer Y, Zürcher M, Sun D, Bergmann A, NeuroTransData Study Group.   +9 more
europepmc   +1 more source

A computational approach to drug design for multiple sclerosis via QSPR modeling, chemical graph theory, and multi-criteria decision analysis. [PDF]

BMC Chem
Farooq FB, Idrees N, Noor E, Alqahtani NA, Imran M.   +4 more
europepmc   +1 more source

The Effects of Diroximel Fumarate on Ferroptotic Glial Cell Death and Demyelination

openaire   +2 more sources

Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments. [PDF]

Mult Scler J Exp Transl Clin
Lin WZ, Lee JJ, Chertcoff A, Tremlett H, Kramer JLK.   +4 more
europepmc   +1 more source

Targeting the mitochondrial metabolite-dynamics-MDVs-MitoEVs axis: a new frontier in osteoarthritis management. [PDF]

J Transl Med
Zhang T, Zhang H, Chen X, Liu Y, Han X, Zhu W, Liu Y, Zeng G, Jiao K.   +8 more
europepmc   +1 more source